Uveal Melanoma
Symptoms, Doctors, Treatments, Advances & More

Learn About Uveal Melanoma

What is the definition of Uveal Melanoma?
Intraocular melanoma is a cancer of the pigment-producing cells (melanocytes) in the middle layer of the eye, called the uveal tract. The uveal tract has 3 main parts: (1) the choroid (the tissue layer filled with blood vessels); (2) the ciliary body (the ring of muscle tissue that changes the size of the pupil and the shape of the lens); and (3) the iris (the colored part of the eye). Most cases of Intraocular melanoma develop in the choroid, called choroidal melanoma. The ciliary body is less commonly a site of origin, and the iris is the least common. Each manifests with different clinical features and symptoms.
What are the alternative names for Uveal Melanoma?
  • Intraocular melanoma
  • Melanoma of the Uvea
  • Uveal melanoma
Who are the top Uveal Melanoma Local Doctors?
Elite in Uveal Melanoma
Hematology | Oncology
Elite in Uveal Melanoma
Hematology | Oncology
Referral may be required

Northwell Health Center For Advanced Medicine, RJ Zuckerberg Cancer Center

450 Lakeville Road, Entrance B, 
Lake Success, NY 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Richard Carvajal is a Hematologist and an Oncologist practicing medicine in Lake Success, New York. Dr. Carvajal is rated as an Elite provider by MediFind in the treatment of Uveal Melanoma. He is also highly rated in 8 other conditions, according to our data. His clinical expertise encompasses Metastatic Uveal Melanoma, Uveal Melanoma, Melanoma of the Eye, Melanoma, and Tissue Biopsy. Dr. Carvajal is board certified in American Board Of Internal Medicine/Medical Oncology. Dr. Carvajal is currently accepting new patients.

Elite in Uveal Melanoma
Ophthalmology | Oncology
Elite in Uveal Melanoma
Ophthalmology | Oncology
Referral may be required

Ophthalmology - Wills Eye Hospital

840 Walnut Street, Floor 10, 
Philadelphia, PA 
Languages Spoken:
English
Accepting New Patients
Offers Telehealth

Carol Shields is an Oncologist and an Ophthalmologist practicing medicine in Philadelphia, Pennsylvania. Dr. Shields is rated as an Elite provider by MediFind in the treatment of Uveal Melanoma. She is also highly rated in 49 other conditions, according to our data. Her clinical expertise encompasses Retinoblastoma, Melanoma of the Eye, Uveal Melanoma, Vitrectomy, and Iridectomy. Dr. Shields is board certified in Ophthalmology. Dr. Shields is currently accepting new patients.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Uveal Melanoma
Elite in Uveal Melanoma
Referral may be required
Paris, FR 

Sophie Neumann-Piperno practices practicing medicine in Paris, France. Ms. Neumann-Piperno is rated as an Elite expert by MediFind in the treatment of Uveal Melanoma. She is also highly rated in 18 other conditions, according to our data. Her clinical expertise encompasses Metastatic Uveal Melanoma, Uveal Melanoma, Adult Soft Tissue Sarcoma, Hysterectomy, and Tissue Biopsy.

What are the latest Uveal Melanoma Clinical Trials?
A Randomized, Phase 3, Open-label Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma

Summary: This is a randomized, multi-center, open-label study of adjuvant darovasertib in participants with non-metastatic uveal melanoma (OptimUM-11)

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase 1 and 2 First-in-human, Open-label, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of VMD-102 in Participants With Hepatocellular Carcinoma and Other Advanced Solid Tumors

Summary: This study is to evaluate the safety and tolerability to determine (i) the recommended Phase 2 dose (RP2D) of VMD-102 (Phase 1), and (ii) preliminary anti-tumor efficacy (Phase 2), in participants with advanced HCC, metastatic uveal melanoma (MUM), renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and colorectal cancer (CRC). The pharmacokinetics (PK), preliminary anti-tumor activity...

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center